Canada markets closed

Glaukos Corp. Registered Shares (6GJ.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
43.40-0.40 (-0.91%)
At close: 4:39PM CEST
Full screen
Previous Close43.80
Open44.00
Bid43.00 x 0
Ask44.00 x 0
Day's Range43.40 - 44.20
52 Week Range39.40 - 80.00
Volume0
Avg. Volume2
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks

    Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

    Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.

  • Business Wire

    Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.

    SAN CLEMENTE, Calif., September 20, 2021--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational ph

  • Business Wire

    Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.

    SAN CLEMENTE, Calif., September 15, 2021--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a settlement agreement with Ivantis, Inc. agreeing to terminate the patent infringement lawsuit Glaukos initiated on April 14, 2018 in the U.S. District Court for the Central District of California, Southern Division, concern